Tenax Therapeutics is trading 5.05% up at $1.98, with no clear company-specific catalyst identified for the October 29 move. - A class-action filing announced October 29 repeats allegations concerning earlier statements about TNX-103; the allegations relate to events disclosed in August, not a new positive development. - The broader market was lower, and available evidence does not indicate the rise followed broad-market sentiment. - Current trading volume or another specific intraday driver was not established.